1 March 2023

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

NOTICE OF INTERIM RESULTS

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, will announce its interim results for the six months ended 31 December 2022 on 14 March 2023.  

Aptamer Group's Chief Executive Officer, Arron Tolley, new incoming Chief Financial Officer, Rob Quinn, and Chief Technical Officer, David Bunka, will be hosting an in-person meeting and webcast for sell-side analysts at 10.00am GMT on 14 March 2023. To register your interest in attending, please email [email protected].

- ENDS -

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley                                                                              +44 (0) 1904 56 7790

SPARK Advisory Partners Limited - Nominated Adviser  

Andrew Emmott / Mark Brady / Adam Dawes                                     +44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy                                       +44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone                              +44 (0) 20 3709 5700

[email protected]

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.